respiratory
Cystic fibrosis

PBS moves for COPD inhalers and new CF treatments


In a major change for corticosteroid/LABA inhalers for COPD, the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended removal of the requirement for patients to have a FEV1 less than 50% of predicted normal prior to therapy. At its March meeting the PBS gatekeeper made the recommendation in response to an application for the triple therapy ...

Already a member?

Enter your email to keep reading.


OR